EA Pharma (Japan)

Recent papers from EA Pharma (Japan)

1. Efficacy and safety of diazepam nasal spray in Japanese Pediatric patients with or at risk for status epilepticus: a phase 3, Multicenter, open-label clinical trialEpilepsy & Behavior Reports · 2026
2. Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in JapanNeurology and Therapy · 2026
3. Current Status of Bowel Preparation for Colonoscopy in Japan: A Web‐Based Survey of Endoscopists (PRESS Survey)DEN Open · 2026
4. Clinical and LAT1 Biomarker Correlates of Clinical Benefit from Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer: A Post Hoc AnalysisCancers · 2026
5. Safety, Pharmacokinetics, Food effect, and Pharmacodynamics of AJM347, a Selective α4β7 Integrin Antagonist: A First‐in‐Human Single‐ and Multiple‐Ascending Dose Study in Healthy Male VolunteersThe Journal of Clinical Pharmacology · 2026
6. Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia veraLeukemia & lymphoma/Leukemia and lymphoma · 2026
7. Nutrition Management and Self-Perceived Relapse Triggers in Patients with Inflammatory Bowel Disease: Results from the 3R Web-Based SurveyCrohn s & Colitis 360 · 2026
8. Clinical immunogenicity and pharmacokinetic assessments of E3112, a recombinant human hepatocyte growth factorFuture Science OA · 2026
9. Prevotella bivia promotes cervical cancer progression and modulates macrophage polarization, while Lactobacillus iners suppresses these processes: evidence from multiomics analysismBio · 2026
10. Real‐World Safety and Effectiveness of Glatiramer Acetate in Patients With Multiple Sclerosis: Final Results of Post‐Marketing Surveillance in JapanNeurology and Clinical Neuroscience · 2026
11. A case study of virtual control group verification using historical control data at a single facilityThe Journal of Toxicological Sciences · 2026
12. Integrated analysis of the ropeginterferon alfa-2b clinical program in essential thrombocythemia to demonstrate molecular and hematologic responses with safety profile information across treatment lines, ethnicities, and driver mutation types.Journal of Clinical Oncology · 2026
13. Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in JapanFrontiers in Psychiatry · 2026
14. Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)Journal of Gastroenterology · 2026
15. Safety and effectiveness of clazosentan in patients after aneurysmal subarachnoid haemorrhage: a second interim report of a post-marketing surveillance in JapanNeurosurgical Review · 2026
16. Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter studyInternational Journal of Hematology · 2026
17. Therapeutic Potential of Ozonized Glycerin in Skin Inflammation and RepairCosmetics · 2026
18. Safety and effectiveness of budesonide rectal foam for ulcerative colitis in a large-scale, multicenter, prospective observational study: final report of post-marketing surveillance in JapanIntestinal Research · 2026
19. Short-Term Efficacy and Safety of Elobixibat for Chronic Constipation Assessed by Rectal Ultrasonography: A Retrospective Observational StudyDiagnostics · 2026
20. Identification of KKL-35 as a Novel Carnosine Dipeptidase 2 (CNDP2) Inhibitor by In Silico ScreeningMolecules · 2025